Every day, the sun rises on Wall Street, and a plethora of
professional analysts wake to issue new opinions on stocks.
Here at the Fool, we use our "This Just In" column to examine
some of these picks-- and
the track recordsof the firms behind them -- so
individuals can make better investing decisions.
In addition to following professional banks, anyone can
use
Motley Fool CAPSto monitor the collective opinions of
more than 140,000 members, many of whom
demonstrate better investing insight than published analysts
do.
After being pummeled down to a two-star
rankearlier this summer, enough top-performing CAPS
members turned bullish on
Cytori Therapeutics (Nasdaq: CYTX) to have it
once again touch
four-starstatus recently. A total of 117 members have
given their opinion on Cytori Therapeutics, with many of them
offering analysis and commentary explaining the recent
optimism.
Many CAPS members are bullish on the future of stem-cell
technologies and expect Cytori's products to become more
widely accepted and applied going forward. Large drugmakers
like
Pfizer (NYSE: PFE),
Johnson & Johnson (NYSE: JNJ), and
sanofi-aventis (NYSE: SNY) have
jumped on the stem-cell bandwagonin recent years, and the
Obama administration recently eased restrictions on stem-cell
research. Cytori sells its products primarily in Europe and
Asia, but it is
increasing its presencein the U.S. as it progresses
through the regulatory pathway.
In recent quarters, the company has been lowering
expenses, narrowing its losses, and boosting its third-party
revenue as it ramps up its Celution and StemSource products
around the world. It recognized $7.3 million in development
revenue from its Olympus partnership in the second quarter,
sending its year-over-year total revenue growth into the
stratosphere, and an expanded deal with
General Electric 's (NYSE: GE) GE Healthcare
shows promise.
The company expects annual revenue growth, but because of
the sales cycle of its products, this can fluctuate
dramatically,
setting up the stock volatilitythat investors in
Geron (Nasdaq: GERN) and
StemCells (Nasdaq: STEM) are familiar
with.
Do you think Cytori Therapeutics deserves its star bump?
Add your thoughts in the comments box below, or head over to
CAPS to
rate it
yourselfand check out all the information and opinions
the community offers. CAPS is totally free.
This article was originally published as
A Big Upgrade for Cytori Therapeuticson
Fool.com
Copyright © 2009 The Motley Fool, LLC. All rights
reserved.
|